Drug Trial Radar · NCT02906020
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
273
Actual
Start
Dec 15, 2016
Primary completion
Dec 18, 2020
Study completion May 27, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: * Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's disease (PD) carrying a glucocerebrosidase gene (GBA) mutation or other pre-specified variants. * Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in participants with early-stage PD carrying a GBA mutation or other pre-specified variants. Secondary Objectives: Part 1: * To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR402671 in plasma when administered in early-stage PD participants carrying a GBA mutation. * To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage PD participants carrying a GBA mutation. Part 2: * To demonstrate overall safety and tolerability of GZ/SAR402671 administered orally for 52 weeks in early-stage PD participants carrying a GBA mutation as compared to placebo. * To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage PD participants carrying a GBA mutation over a 52-week period.
Conditions
- Parkinson's Disease
Interventions
venglustat GZ/SAR402671Drug
Pharmaceutical form: capsule Route of administration: oral
PlaceboDrug
Pharmaceutical form: capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Abnormal Physical Examination FindingsTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Abnormal Neurological Examination FindingsTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: HematologyTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Vital Signs AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
- Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total ScoreTime frame: Baseline to Week 52
Locations
52 sites in 16 countries. Site status is shown where the registry gives one.
Investigational Site Number :8400017
Scottsdale, Arizona
Investigational Site Number :8400011
Scottsdale, Arizona
Investigational Site Number :8400004
La Jolla, California
Investigational Site Number :8400019
Palo Alto, California
Investigational Site Number :8400013
Sunnyvale, California
Investigational Site Number :8400015
New Haven, Connecticut
Investigational Site Number :8400008
Boca Raton, Florida
Investigational Site Number :8400016
Chicago, Illinois
Investigational Site Number :8400005
Chicago, Illinois
Investigational Site Number :8400014
Boston, Massachusetts
Investigational Site Number :8400018
New York, New York
Investigational Site Number :8400010
New York, New York
Investigational Site Number :8400001
New York, New York
Investigational Site Number :8400021
Portland, Oregon
Investigational Site Number :8400020
Portland, Oregon
Investigational Site Number :8400009
Portland, Oregon
Investigational Site Number :8400002
Philadelphia, Pennsylvania
Investigational Site Number :8400006
Fairfax, Virginia
Investigational Site Number :8400012
Kirkland, Washington
Investigational Site Number :0400001
Innsbruck, Austria
Investigational Site Number :1240003
Vancouver, British Columbia, Canada
Investigational Site Number :1240002
Ottawa, Ontario, Canada
Investigational Site Number :1240001
Montreal, Quebec, Canada
Investigational Site Number :2500001
Paris, France
Investigational Site Number :2760002
Kiel, Germany
Investigational Site Number :2760001
Tübingen, Germany
Investigational Site Number :3000002
Larissa, Greece
Investigational Site Number :3760002
Haifa, Israel
Investigational Site Number :3760003
Petah Tikva, Israel
Investigational Site Number :3760001
Tel Aviv, Israel
Investigational Site Number :3760004
Tel HaShomer, Israel
Investigational Site Number :3800001
Catanzaro, Italy
Investigational Site Number :3800004
Milan, Italy
Investigational Site Number :3800003
Pavia, Italy
Investigational Site Number :3800002
Salerno, Italy
Investigational Site Number :3800006
Rozzano, Milano, Italy
Investigational Site Number :3920005
Nagoya, Aichi-ken, Japan
Investigational Site Number :3920002
Kyoto, Kyoto, Japan
Investigational Site Number :3920004
Osaka, Osaka, Japan
Investigational Site Number :3920001
Bunkyo-ku, Tokyo, Japan
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.